Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Intracellular Th (ITCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ITCI (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 7.21% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.05B USD | Price to earnings Ratio - | 1Y Target Price 132 |
Price to earnings Ratio - | 1Y Target Price 132 | ||
Volume (30-day avg) 2415397 | Beta 0.7 | 52 Weeks Range 64.09 - 131.98 | Updated Date 04/1/2025 |
52 Weeks Range 64.09 - 131.98 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.97% | Operating Margin (TTM) -14.66% |
Management Effectiveness
Return on Assets (TTM) -6.96% | Return on Equity (TTM) -8.58% |
Valuation
Trailing PE - | Forward PE 158.73 | Enterprise Value 13069306521 | Price to Sales(TTM) 20.63 |
Enterprise Value 13069306521 | Price to Sales(TTM) 20.63 | ||
Enterprise Value to Revenue 19.21 | Enterprise Value to EBITDA -37.12 | Shares Outstanding 106522000 | Shares Floating 104819158 |
Shares Outstanding 106522000 | Shares Floating 104819158 | ||
Percent Insiders 2.48 | Percent Institutions 96.65 |
Analyst Ratings
Rating 4.53 | Target Price 103.5 | Buy 5 | Strong Buy 9 |
Buy 5 | Strong Buy 9 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Intracellular Th
Company Overview
History and Background
Intracellular Therapies, Inc. is a biopharmaceutical company focused on the discovery and clinical development of innovative, small molecule drugs for the treatment of neuropsychiatric and neurological disorders and diseases. Founded in 2002, the company has focused on addressing unmet needs in mental health. Early efforts involved novel chemistries leading to their lead compound.
Core Business Areas
- CNS Therapeutics Development: Research, development, and commercialization of therapies for central nervous system disorders, including schizophrenia, bipolar disorder, and major depressive disorder.
- Drug Discovery: Discovery and pre-clinical development of novel compounds for neurological and psychiatric conditions.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure consists of research and development, clinical operations, and commercial functions. Corporate governance is overseen by a board of directors.
Top Products and Market Share
Key Offerings
- CAPLYTA (lumateperone): CAPLYTA is an atypical antipsychotic approved for the treatment of schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults. Market share data is continuously evolving, with specific numbers influenced by new drug approvals and clinical trial results. Key competitors include products from Otsuka, Alkermes and AbbVie. Revenue from this product constitutes the majority of company revenue.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the neuropsychiatry segment, is characterized by high unmet medical needs and significant market potential. It's driven by advancements in neuroscience, increasing prevalence of mental health disorders, and growing awareness and acceptance of treatment.
Positioning
Intracellular Therapies is positioned as an innovator in CNS drug development, with a focus on novel mechanisms of action and improved therapeutic profiles. Its competitive advantage lies in its proprietary chemistry and differentiated approach to treating mental health disorders.
Total Addressable Market (TAM)
The TAM for antipsychotics and mood stabilizers is estimated to be in the billions of dollars annually. Intracellular Therapies is positioned to capture a portion of this market through the growth of CAPLYTA and further pipeline development.
Upturn SWOT Analysis
Strengths
- Approved and marketed drug (CAPLYTA)
- Proprietary chemistry platform
- Strong intellectual property position
- Experienced management team
Weaknesses
- Reliance on a single marketed product (CAPLYTA)
- Limited sales and marketing infrastructure compared to larger pharmaceutical companies
- High R&D expenses
- Risk associated with clinical trial outcomes
Opportunities
- Expansion of CAPLYTA's label to additional indications
- Development of new pipeline candidates
- Strategic partnerships and collaborations
- Increasing awareness and diagnosis of mental health disorders
Threats
- Competition from established pharmaceutical companies
- Generic entry of CAPLYTA after patent expiration
- Regulatory hurdles and delays
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- ALKS
- OTSKF
Competitive Landscape
Intracellular Therapies competes with established pharmaceutical companies. Its advantages include its novel mechanism of action and differentiated product profile. Disadvantages include limited resources compared to larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the launch and commercialization of CAPLYTA.
Future Projections: Analyst estimates project continued revenue growth driven by CAPLYTA sales and potential pipeline advancements.
Recent Initiatives: Recent initiatives include clinical trials for new indications, strategic partnerships, and expansion of the sales force.
Summary
Intracellular Therapies has a novel approved product, CAPLYTA, driving revenue growth, but relies heavily on it. Its pipeline and strategic partnerships provide future opportunities. However, ITCI faces significant competition from larger pharmaceutical companies and regulatory risks, requiring careful management of resources to capitalize on its potential.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
ALKS
Alkermes Plc
ALKS
Alkermes Plc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
Sources and Disclaimers
Data Sources:
- Intracellular Therapies Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Market Research Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data and financial information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intracellular Th
Exchange NASDAQ | Headquaters Bedminster, NJ, United States | ||
IPO Launch date 2014-01-07 | Co-Founder, Chairman & CEO Dr. Sharon Mates Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 860 | |
Full time employees 860 | |||
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder. In addition, the company develops lenrispodun (ITI-214) in Phase 2 clinical trial for the treatment of Parkinson's disease; ITI-1284-ODT-SL in Phase 2 trial for the treatment of generalized anxiety disorder, and psychosis and agitation in patients with Alzheimer's disease; ITI-1020 in Phase 1 trial for cancer immunotherapy; and ITI-1549 in preclinical studies for mood and anxiety disorders. It distributes its products through third-party wholesale drug distributors. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in Bedminster, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.